This product is a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx in vascular smooth muscle and myocardium, but mainly acts on blood vessels, so it has strong vascular selectivity. It causes dilation of systemic blood vessels such as coronary arteries and renal arterioles, producing a hypotensive effect.

This product is a macrolide antibiotic. Its mechanism of action is similar to that of erythromycin, and its antibacterial spectrum is also similar to that of erythromycin, but its antibacterial activity against most Gram-positive bacteria is slightly worse. Some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin. This product also has considerable activity against diphtheria, tetani, Neisseria gonorrhoeae, pertussis, Rickettsia and Chlamydia trachomatis.

It acts on the lower brain stem of the central nervous system, inhibits multi-synaptic reflexes, blocks nerve conduction from abnormally excited muscles, and produces muscle relaxation. It also acts on the higher centers of the cerebral cortex and has a weak sedative effect.

Antibacterial drug. It is relatively stable against the β-lactamase produced by Staphylococcus aureus, so it has a strong antibacterial effect against Gram-positive bacteria; it is unstable against the β-lactamase produced by Gram-negative bacteria, so it has a weaker effect against Gram-negative bacteria, and is ineffective against Pseudomonas aeruginosa and anaerobic bacteria.

It can form a thin film on the surface of damaged gastric mucosa, thereby resisting the invasion of gastric acid on the mucosa and protecting the gastric mucosa. In addition, sucralfate can absorb pepsin and neutralize gastric acid, but the effect is weak.